Managing Hypertriglyceridemia with Lovaza and Vascepa

Cardiovascular Risk Reduction

• The American College of Cardiology recommends Vascepa for cardiovascular risk reduction in patients with triglycerides ≥150 mg/dL on statin therapy with established ASCVD or diabetes plus risk factors, as it reduces major adverse cardiovascular events by 25% in the REDUCE-IT trial 1, 2
• The American College of Cardiology states that Lovaza has not demonstrated cardiovascular mortality or morbidity reduction in clinical trials, and the STRENGTH trial with omega-3 carboxylic acids was stopped for futility, showing no cardiovascular benefit 1, 3

FDA-Approved Indications and Guideline Recommendations

• The FDA approves Vascepa for cardiovascular risk reduction in patients with triglycerides ≥150 mg/dL on maximally tolerated statin therapy with established ASCVD or diabetes plus ≥2 risk factors, as recommended by the 2024 DCRM guidelines 4, 5
• The FDA approves Lovaza only as adjunct to diet for severe hypertriglyceridemia (≥500 mg/dL), with no cardiovascular indication, and current guidelines do not recommend Lovaza for cardiovascular risk reduction in patients with moderate hypertriglyceridemia 4, 5

LDL-Cholesterol Effects and Monitoring

• Lovaza may increase LDL-C by 5-10% due to its DHA content, requiring periodic monitoring during therapy, as recommended by the Praxis Medical Insights 5
• Vascepa does not increase LDL-C because it contains only EPA without DHA, and monitoring LDL-C levels is crucial when using Lovaza to ensure no excessive increase 5

Treatment Goals and Insurance Coverage

• If the goal is cardiovascular risk reduction, Vascepa is strongly preferred, and prior authorization should emphasize the cardiovascular outcomes data from REDUCE-IT if patient meets criteria (TG ≥150 mg/dL, on statin, with ASCVD or diabetes plus risk factors) 1, 2
• Patient assistance programs for Vascepa may be available if insurance denies coverage, and generic omega-3-acid ethyl esters may be more affordable than brand-name Lovaza 5

Safety Considerations and Common Pitfalls

• Monitor LDL-C levels 4-8 weeks after initiation of Lovaza to ensure no excessive increase, and monitor for atrial fibrillation risk, gastrointestinal disturbances, skin changes, and bleeding 5
• Do not assume Lovaza and Vascepa are interchangeable for cardiovascular risk reduction, and do not use over-the-counter fish oil supplements as substitutes for prescription products, as recommended by the Praxis Medical Insights 4, 1, 2, 5, 6